Molecular comparison of human and mouse pulmonary adenocarcinomas

Experimental Lung Research

Volumn 24, Issue 4, 1998, Pages 541-555

  Malkinson, Alvin M ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Neoplastic progression; Oncogenes; Tumor suppressor genes

Indexed keywords

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; CELL ULTRASTRUCTURE; CLARA CELL; CONFERENCE PAPER; CONTROLLED STUDY; DNA METHYLATION; GENE DELETION; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0031804606     PISSN: 01902148     EISSN: None     Source Type: Journal    
DOI: 10.3109/01902149809087385     Document Type: Conference Paper

References (69)

1. Lovejoy EA, Clarke AR, Harrison DJ. Animal models and the molecular pathology of cancer. J. Pathol. 1997;181:130-135.
2. Morganbesser SD, Williams BO, Jacks T, de Pinho RA. p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature. 1994;371:72-74.
3. Malkinson AM, Belinsky SA. The use of animal models in preclinical studies. In: Pass HL, Mitchell J, Johnson DH, Turrisi AT, eds. Lung Cancer: Principles and Practice. Philadelphia: Lippincott;1996:273-284.
4. Cardiff RD, Munn RJ. Comparative pathology of mammary tumorigenesis in transgenic mice. Cancer Lett. 1995;90:13-19.
5. Travis WD, Linder J, Mackay B. Classification, histology, cytology, and electron microscopy. In: Pass HL, Mitchell J, Johnson DH, Turrisi AT, eds. Lung Cancer: Principles and Practice. Philadelphia: Lippincott;1996:361-395.
6. Hammar SP. Common neoplasms, In: Dail DH, Hammer SP, Colby TV, eds. Pulmonary Pathology - Tumors. New York: Springer; 1995:1-156.
7. Schottenfeld D, Epidemiology of lung cancer. In: Pass HL, Mitchell J, Johnson DH, Turrisi AT, eds. Lung Cancer: Principles and Practice. Philadelphia: Lippincott;1996:305-321.
8. Osann KE. Lung cancer in women: the importance of smoking, family history of cancer, and medical history of respiratory disease. Cancer Res. 1991;51:4893-4897.
9. McDuffie HH, Klaassen DJ, Dosman JA. Characteristics of patients with pulmonary lung cancer diagnosed at age 50 years or younger. Chest. 1989;96:1298-1301.
10. Cooper CA, Carey FA, Bubb VJ, Lamb D, Kerr KM, Wyllie AH. The pattern of K-ras mutation in pulmonary adenocarcinoma defines a new pathway of tumor development in the human lung. J Pathol. 1997;181:401-404.
11. Westra WH, Bass IO, Hruban RH, Askin F, Wilson K, Offerhaus JA, Slebos RJC. K-ras oncogene mutations in atypical alveolar hyperplasias of the human lung. Cancer Res. 1996;56:2224-2226.
12. Kauffman SL. Histogenesis of the papillary Clara cell adenoma. Am J Pathol. 1981;103:174-180.
13. Thaete LG, Beer DG, Malkinson AM. Genetic variation in the proliferation of pulmonary type II cells: basal rates and alterations following urethane treatment. Cancer Res. 1986;46:5335-5338.
14. Roggli VL, Volmer RT, Greenberg SD, McGavran MH, Spjut HJ, Yesner R. Lung cancer heterogeneity: a blinded and randomized study of 100 consecutive cases. Human Pathol. 1985;16:569-579.
15. Liebow AA. Bronchiolo-alveolar carcinoma. Adv Intern Med. 1960;10:329-358.
16. Auerbach O, Garfinkel L. The changing pattern of lung carcinoma. Cancer. 1991;68:1973-1977.
17. Gazdar AF, Linnoila RI. The pathology of lung cancer: changing concepts and newer diagnostic techniques. Semin Oncol. 1988;15:215-225.
18. Johnson BE, Molecular biology of lung cancer. In: Mendelsohn J, Howley PM, Isreal MA, Liotta A, eds. The Molecular Basis of Cancer. Philadelphia: Saunders. 1995:317-339.
19. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682-4689.
20. Mills NE, Fishman CL, Rom WN, Dubin N, Jacobson DR. Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma. Cancer Res. 1995;55:1444-1447.
21. Westra WH, Slebos RJC, Offerhaus GJA, et al. K-ras oncogene activation in lung adenocarcinomas from former smokers. Cancer. 1993;72:432-438.
22. Slebos RJC, Hruban, RH, Dalesio O., Mooi WJ, Offerhaus JA, Rodenhuis S. Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J Natl Cancer Inst. 1991;83:1024-1027.
23. Vahakangas KH, Samet JM, Metcalf RA, et al. Mutations of p53 and ras genes in radon associated lung cancer from uranium miners. Lancet. 1992;336:576-580.
24. Reddel RR, Ke Y, Kaighn ME, et al. Human bronchial epithelial cells neoplastically transformed by v-Ki-ras: Altered response to inducers of terminally squamous differentiation. Oncogene Res. 1998;3:401-408.
25. You M, Candrian U, Maronpot RR, Stoner GD, Anderson MW. Activation of Ki-ras protooncogene in spontaneously occurring and chemically-induced lung tumors of the strain A mouse. Proc Natl Acad Sci USA, 1989;86:3070-3074.
26. Stanley L. Molecular aspects of chemical carcinogenesis : the role of oncogenes and tumor suppressor genes. Toxicology. 1995;96:175-194.
27. Nuzum EO, Malkinson AM, Beer DG. Specific K-ras codon 61 mutations may determine the development of mouse lung adenomas or adenocarcinomas. Mol Carcinog. 1990;3:287-295.
28. Li EE, Heflich H, Bucci TJ, Manjanatha MG, Blaydes BS, Delclos KB. Relationships of DNA adduct formation, K-ras activating mutations and tumorigenic activities of 6-nitrochrysene and its metabolites in the lungs of CD-1 mice. Carcinogenesis. 1994;15:1377-1385.
29. Leone-Kabler S, Wessner LL, McEntee MF, D'Agostino RB Jr, Miller MS. Ki-ras mutations are an early event and correlate with tumor stage in transplacentally -induced murine lung tumors. Carcinogenesis. 1997;18:1163-1168.
30. Belinksy SA, Devereux TR, Foley JF, White CM, Maronpot RR, Anderson MW. The role of alveolar type 2 cells in the development and progression of pulmonary tumors in the A/J mouse. Cancer Res. 1992;52:3164-3173.
31. Horio Y, Schrump DS, Chen A, Rice P, Malkinson AK, Roth JA. K-ras and p53 mutations are early and late events, respectively, in urethane induced pulmonary carcinogenesis. Mol Carcinog. 1996;17:217-223.
32. Ichikawa T, Yano Y, Ochida M, Otani S, Hagiwana K, Yano T. The activation of the K-ras gene at an early stage of lung tumorigenesis in mice. Cancer Lett. 1996;107:165-170.
33. 6-methylguanine DNA adduct levels and Ki-ras activation in lung tumors from resistant and susceptible mouse strains. Mol Carcinog. 1993;8:177-185.
34. Lin L, Festing MFW, Devereux TR, et al. Additional evidence that the K-ras protooncogene is a candidate for the major mouse pulmonary adenoma susceptibility (Pas-1) gene. Exp Lung Res. 1998;24:481-497.
35. Storm SM, Rapp UR. Oncogene activation: C-raf-1 gene mutation in experimental and naturally occurring tumors. Toxicol Lett. 1993;67:201-210.
36. Dittardi R, Gion M, Pagan V, et al. Epidermal growth factor receptors in lung malignancies: comparison between cancer and normal tissues. Br J Cancer. 1991;64:741-744.
37. Liu C, Tsao MS. In vitro and in vivo expression of transforming growth factors α and tyrosine kinase receptors in human non-small lung carcinoma. Am J Pathol. 1993;142:1155-1162.
38. Miller RR, Nelems B, Evans KG, Muller NL, Ostrow DN. Glandular neoplasia of the lung: a proposed analogy to colon tumors. Cancer. 1988;61:1009-1014.
39. Miller, R.R. Bronchioloalveolar cell adenoma. Am J Surg Pathol. 1990;14:904-912.
40. Rice PL, Dwyer-Nield LD, Miller ACK, Kazlauskas A, Malkinson A. Reduced concentrations of signal transducing effector molecules in multistage carcinogenesis in mice. Proc Am Assoc Cancer Res. 1996;37:105.
41. Stewart HL, Dunn TB, Snell KC, Deringer MK. Tumors of the respiratory tract. In: Turosov VS, ed. Pathology of Tumors in Laboratory Animals. Lyon: IARC;1979:251-288.
42. Xiao S, Daizong L, Corson JM, Vijg J, Fletcher JA. Codeletion of p15 and p16 genes in primary non-small cell lung carcinoma. Cancer Res. 1995;55:2968-2971.
43. Merlo A, Herman JG, Mao, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CKDN2/MTS1 in human cancers. Nature Med. 1995;1:686-692.
44. Herzog CR, Wiseman RW, You M. Deletion mapping of a putative tumor suppressor gene on chromosome 4 in mouse lung tumors. Cancer Res. 1994;54:4007-4010.
45. INK4B/ MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res. 1995;55:1448-1451.
46. INK4a in mouse lung tumors. Carcinogenesis. 1997;18:115-120.
47. Belinsky SA, Nikula KJ, Baylin SB, Issa JPJ. Increased cytosine DNA-methyltransferase activity is target cell-specific and an early event in lung cancer. Proc Natl Acad Sci USA. 1996;93:4045-4050.
48. Schauer IE, Siriwardana S, Langan TA, Sclafani RA. Cyclin D1 overexpression vs retinoblastoma activation: Implication for growth control regulation in non-small and small cell lung cancer. Proc Natl Acad Sci USA. 1994;91:7827-7831.
49. Malkinson AM, Mamay C, Schauer I, et al. Cyclin D1 as a proliferative marker regulating retinoblastoma phosphorylatin in mouse lung epithelial cells. In preparation.
50. Schrump DS, Chen A, Consoli U. Inhibition of lung cancer proliferation by antisense cyclin D. Cancer Gene Ther. 1996;3:131-135.
51. Fong KM, Zimmerman PV, Smith PJ. Tumor progression and loss of heterozygosity at 5q and 18q in non-small cell lung cancer. Cancer Res. 1995;55:222-223.
52. Oreffo VIC, Robinson S, You M, Wu MC, Malkinson AM. Decreased expression of adenomatous polyposis coli (Apc) and mutated in colon cancer (Mcc) genes in mouse lung neoplasia. Mol Carcinog. 1998;21:37-50.
53. Cesen-Cummings K, Fernstrom MJ, Malkinson AM, Ruch RJ. Frequent reduction of gap junctional intercellular communication and connexin 43 expression in human and mouse lung Carcinogenesis. Carcinogenesis. 1998;19:61-68.
54. Malinkson AM, Koski KM, Evans WA, Festing MFW. Exposure toobutylated hydroxytoluene is necessary for lung tumor development in BALB mice treated with low doses of 3-methylcholanthrene. Cancer Res. 1997;57:2832-2834.
55. Testa JR. Chromosome alterations in human lung cancer. In: Pass HL, Mitchell J, Johnson DH, Turrisi AT, eds. Lung Cancer: Principles and Practice. Philadelphia: Lippincott ; 1996:55-72.
56. Petersen I, Bujard M, Petersen S, et al. Patterns of chromosomal imbalances in adenocarcinoma and squamous cell carcinoma of the lungs. Cancer Res. 1997;57:2331-2335.
57. Malkinson AM, Siegel D, Forrest GL, et al. Elevated DT-diaphorase activity and mRNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin C. Cancer Res. 1992;52:4753-4757.
58. Thaete LG, Siegel D, Malkinson AM, Ross D. NAD(P)H: quinone oxidoreductase (DT-diaphorase) activities in normal and neoplatic mouse lung epithelia. Int J Cancer. 1991;49:145-149.
59. Zhang L, Zhou W, Velculescu VE, et al. Gene expression profiles in normal and cancer cells. Science. 1997;276:1268-1272.
60. Sandgren EP, Quaife CJ, Pinkert CA, Palmiter RD, Brinster RL. Oncogene-induced liver neoplasia in transgenic mice. Oncogene. 1989;4:323-330.
61. Johnson BE, Ihde DC, Makuch RW, et al. Myc family oncogene amplication in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course. J Clin Invest. 1987;79:1629-1634.
62. Polly P, Nicholson RC. High levels of c-myc gene expression precede point mutational activation of Ki-ras in mouse lung cancer. Cancer Lett. 1994;76:87-92.
63. ink4b in mouse lung tumor cell lines. Oncogene. 1996;13:1885-1891.
64. Yokota J, Akiyama T, Fung YK, et al. Altered expression of the retinoblastoma (RB) gene in small-cell carcinoma of the lung. Oncogene 1988;3:471-475.
65. Carbone D, Kratzke R. RB and p53 genes. In: Pass HL, Mitchell J, Johnson DH, Turrisi AT, eds. Lung Cancer: Principles and Practice. Philadelphia: Lippincott; 1996:107-122.
66. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356:215-221.
67. D'Amico D, Carbone DP, Johnson BE, Meltzer SJ, Minna JD. Polymorphic sites within the MCC and APC loci reveal very frequent loss of heterozygosity in human small cell lung cancer. Cancer Res. 1992;52:1996-1999.
68. Ruch RJ, Cesen-Cummings K, Malkinson AM. Role of gap junctions in lung neoplasia. Exp Lung Res. 1998;24:523-539.
69. Pezzella F, Turley H, Kuzu I, et al. BCL-2 protein in non-small-cell lung carcinoma: immunohistochemical evidence of abnormal expression and correlation with survival. N Engl J Med. 1993;329:690-694.